Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.4265 -0.0345 (-7.48%)
Streaming Delayed Price Updated: 3:52 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Peering Into Sangamo Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
4 Analysts Assess Sangamo Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today? ↗
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
Via InvestorPlace
News headline image
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings ↗
 
Via Benzinga
News headline image
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study ↗
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate. 
Via Benzinga
News headline image
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
From Sangamo Therapeutics, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
News headline image
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance. 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.